vs
Apellis Pharmaceuticals, Inc.（APLS）与合众银行（CUBI）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$236.9M vs $199.9M），合众银行同比增速更快（21.8% vs -5.9%），合众银行自由现金流更多（$481.0M vs $-14.3M），过去两年合众银行的营收复合增速更高（14.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
合众银行是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的跨国银行机构，2025年位列美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性。旗下核心运营主体为美国合众银行全国协会，提供银行、投资、按揭等多元金融服务。
APLS vs CUBI — 直观对比
营收规模更大
CUBI
是对方的1.2倍
$199.9M
营收增速更快
CUBI
高出27.7%
-5.9%
自由现金流更多
CUBI
多$495.3M
$-14.3M
两年增速更快
CUBI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $236.9M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 41.1% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 21.8% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $2.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCUBI
| Q4 25 | $199.9M | $236.9M | ||
| Q3 25 | $458.6M | $232.1M | ||
| Q2 25 | $178.5M | $206.3M | ||
| Q1 25 | $166.8M | $143.0M | ||
| Q4 24 | $212.5M | $167.8M | ||
| Q3 24 | $196.8M | $167.1M | ||
| Q2 24 | $199.7M | $198.7M | ||
| Q1 24 | $172.3M | $181.6M |
净利润APLSCUBI
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $75.7M | ||
| Q2 25 | $-42.2M | $60.9M | ||
| Q1 25 | $-92.2M | $12.9M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $46.7M | ||
| Q2 24 | $-37.7M | $58.1M | ||
| Q1 24 | $-66.4M | $49.7M |
营业利润率APLSCUBI
| Q4 25 | -25.6% | 41.1% | ||
| Q3 25 | 48.7% | 43.2% | ||
| Q2 25 | -18.6% | 38.2% | ||
| Q1 25 | -50.0% | 8.3% | ||
| Q4 24 | -12.3% | 21.4% | ||
| Q3 24 | -24.0% | 27.5% | ||
| Q2 24 | -14.7% | 38.8% | ||
| Q1 24 | -36.0% | 36.0% |
净利率APLSCUBI
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 32.6% | ||
| Q2 25 | -23.6% | 29.5% | ||
| Q1 25 | -55.3% | 9.0% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 28.0% | ||
| Q2 24 | -18.9% | 29.2% | ||
| Q1 24 | -38.5% | 27.4% |
每股收益（稀释后）APLSCUBI
| Q4 25 | $-0.40 | $2.04 | ||
| Q3 25 | $1.67 | $2.20 | ||
| Q2 25 | $-0.33 | $1.73 | ||
| Q1 25 | $-0.74 | $0.29 | ||
| Q4 24 | $-0.30 | $0.72 | ||
| Q3 24 | $-0.46 | $1.31 | ||
| Q2 24 | $-0.30 | $1.66 | ||
| Q1 24 | $-0.54 | $1.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $4.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.1B |
| 总资产 | $1.1B | $24.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCUBI
| Q4 25 | $466.2M | $4.4B | ||
| Q3 25 | $479.2M | $4.2B | ||
| Q2 25 | $370.0M | $3.5B | ||
| Q1 25 | $358.4M | $3.4B | ||
| Q4 24 | $411.3M | $3.8B | ||
| Q3 24 | $396.9M | $3.1B | ||
| Q2 24 | $360.1M | $3.0B | ||
| Q1 24 | $325.9M | $3.7B |
总债务APLSCUBI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCUBI
| Q4 25 | $370.1M | $2.1B | ||
| Q3 25 | $401.2M | $2.1B | ||
| Q2 25 | $156.3M | $1.9B | ||
| Q1 25 | $164.2M | $1.9B | ||
| Q4 24 | $228.5M | $1.8B | ||
| Q3 24 | $237.1M | $1.8B | ||
| Q2 24 | $264.3M | $1.7B | ||
| Q1 24 | $266.7M | $1.7B |
总资产APLSCUBI
| Q4 25 | $1.1B | $24.9B | ||
| Q3 25 | $1.1B | $24.3B | ||
| Q2 25 | $821.4M | $22.6B | ||
| Q1 25 | $807.3M | $22.4B | ||
| Q4 24 | $885.1M | $22.3B | ||
| Q3 24 | $901.9M | $21.5B | ||
| Q2 24 | $904.5M | $20.9B | ||
| Q1 24 | $831.9M | $21.3B |
负债/权益比APLSCUBI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $494.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $481.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 203.0% |
| 资本支出强度资本支出/营收 | 0.1% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $843.0M |
8季度趋势，按日历期对齐
经营现金流APLSCUBI
| Q4 25 | $-14.2M | $494.8M | ||
| Q3 25 | $108.5M | $116.9M | ||
| Q2 25 | $4.4M | $162.2M | ||
| Q1 25 | $-53.4M | $94.1M | ||
| Q4 24 | $19.4M | $145.1M | ||
| Q3 24 | $34.1M | $24.4M | ||
| Q2 24 | $-8.3M | $6.1M | ||
| Q1 24 | $-133.0M | $-18.8M |
自由现金流APLSCUBI
| Q4 25 | $-14.3M | $481.0M | ||
| Q3 25 | $108.3M | $106.4M | ||
| Q2 25 | $4.4M | $162.1M | ||
| Q1 25 | $-53.4M | $93.4M | ||
| Q4 24 | $19.3M | $143.6M | ||
| Q3 24 | — | $24.1M | ||
| Q2 24 | $-8.4M | $5.8M | ||
| Q1 24 | $-133.3M | $-19.2M |
自由现金流率APLSCUBI
| Q4 25 | -7.1% | 203.0% | ||
| Q3 25 | 23.6% | 45.9% | ||
| Q2 25 | 2.5% | 78.6% | ||
| Q1 25 | -32.0% | 65.4% | ||
| Q4 24 | 9.1% | 85.5% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | -4.2% | 2.9% | ||
| Q1 24 | -77.3% | -10.6% |
资本支出强度APLSCUBI
| Q4 25 | 0.1% | 5.8% | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.2% |
现金转化率APLSCUBI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.54× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 7.29× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | -0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CUBI
暂无分部数据
